What most patients feel in the first 72 hours

For most people, the first two to three days after a ChondroFiller® injection follow a predictable pattern — and knowing what to expect makes the experience considerably easier to navigate.

The collagen scaffold is placed into the cartilage defect under ultrasound guidance during an outpatient appointment, without the recovery burden of surgical cartilage repair. Once it gels in situ, your joint begins responding to the presence of the new scaffold. That response typically takes three forms:

• Localised swelling, which tends to peak at around 24 hours and then gradually subsides. This is the joint's natural reaction to any intra-articular procedure, not a warning sign.
• A dull aching pain flare, often described as a deep, pressure-like discomfort rather than sharp pain. It mirrors the inflammatory signalling that scaffolded repair requires.
• Stiffness, which most patients notice alongside the swelling and which eases as the acute response settles — usually within 48 to 72 hours.

None of these effects require hospitalisation. Standard rest and gentle elevation of the limb help manage them in the first day or two, and they resolve without intervention in the vast majority of cases.

These are physiological responses to the scaffold being present in the joint, not indicators that something has gone wrong. Understanding that distinction is the first step in interpreting your recovery accurately.

Symptoms that need prompt clinical attention

Two adverse events are worth knowing before treatment, not because they are common, but because they carry specific warning signs that should prompt a call to the clinic.

Infection

Any intra-articular injection carries an inherent infection risk, and ChondroFiller® is no exception. The signals to watch for are distinct from the expected swelling described above: increasing warmth around the joint, spreading redness, swelling that worsens rather than improves after the first 48 hours, or the onset of fever. These patterns after 72 hours are not part of a normal scaffold response and should be reviewed promptly — same-day contact with the treating clinic is appropriate if they appear.

Allergic and hypersensitivity reactions

ChondroFiller® is derived from ultrapure, native Type I collagen sourced from murine (rat tail) tissue. Patients with a known allergy or hypersensitivity to collagen or to rodent proteins are absolutely contraindicated and should not receive the treatment at all — this is screened at the pre-treatment assessment stage, so it rarely presents as a post-procedure event. Where it does occur, signs include unusual localised swelling, itching, or systemic allergic features, and require urgent clinical review.

Non-gelation: a procedural note, not a patient symptom

The most commonly logged device issue — the scaffold failing to gel correctly inside the defect — occurs in roughly 0.01% of cases. Importantly, this is a procedural outcome rather than a patient-harm event; it does not produce additional symptoms that patients would notice or need to manage at home.

Patients should leave their appointment with clear written guidance covering these signals and a direct contact number for the treating team.

Who ChondroFiller is not suitable for

The safety record established across more than 19,000 treated cases does not exist in a vacuum — it reflects what is achievable when ChondroFiller® is offered to the right patients. The consultant-led assessment process is what creates that carefully screened cohort, and the 0% serious adverse device effect rate applies only within it, not to broader populations with diffuse joint disease.

Several situations rule out ChondroFiller® on clinical grounds:

• Active joint infection — introducing a scaffold into an infected joint is unsafe regardless of the device; treatment cannot proceed until infection is resolved.
• Known allergy to collagen or murine (rat) proteins — as noted in the context of hypersensitivity risk, this is an absolute contraindication identified at assessment, not after treatment.
• Bleeding disorders or ongoing anticoagulant therapy — these increase procedural and post-procedure haemarthrosis risk.
• Widespread multi-compartmental osteoarthritis or severe limb malalignment — ChondroFiller® addresses focal defects; it cannot compensate for a mechanically compromised joint environment.
• Cartilage defects typically ≥2.5 cm in diameter — the scaffold is designed for contained focal lesions with healthy surrounding cartilage borders.

The clinical logic behind this list matters: ChondroFiller® is indicated for isolated Grade III/IV defects in otherwise well-aligned, infection-free joints. Patients who fall outside that profile are not simply turned away — they are directed towards the pathway that does suit their presentation. Identifying which category a patient falls into is precisely what the assessment appointment is for.

What the post-market safety data actually shows

Twelve years of post-market surveillance, collated in Meidrix Biomedicals GmbH's Clinical Evaluation Report (CER Version 09, April 2025), puts an overall device complaint rate of approximately 0.06% against a dataset of more than 19,000 treated cases — a figure the report describes as among the lowest recorded for any cartilage-repair intervention. Across that entire dataset, zero serious adverse device effects (SADEs) have been logged. A serious adverse device effect is defined as an unintended consequence causing organ damage, hospitalisation, or lasting injury: the distinction matters, because it sets a high bar that the surveillance data clears entirely.

The picture is independently corroborated — at least in part — by a 2025 prospective study by Matta et al. (PMC12498443), which found no significant difference in complications between ChondroFiller-treated patients and controls in wrist cartilage repair. One peer-reviewed study covering a single joint site is not the same as a large multi-joint RCT, but it does provide external validation outside the manufacturer's own programme.

To put the 0.06% figure in clinical perspective: ACI and MACI carry complication rates of up to 17% and reoperation rates reaching 37%; microfracture reoperation rates extend to 41%. ChondroFiller's reoperation rate sits at approximately 3–8% in available cohort data.

The principal limitation of this evidence base deserves plain acknowledgement: no published blinded randomised controlled trial exists. All large-scale safety figures derive from the manufacturer's post-market clinical follow-up programme. That does not invalidate the data, but it is the appropriate frame for interpreting it.

Longer-term imaging findings worth knowing about

Imaging tells a different story from symptoms, and understanding that distinction is useful preparation for any follow-up MRI after a ChondroFiller® injection.

The Schneider et al. controlled, randomised, multicentre study — which compared ChondroFiller® liquid with microfracturing in patients with focal cartilage defects — documented several MRI-detectable findings: bone marrow oedema, irregular structuring at the bone-cartilage border, fibrocartilage conformation, and shrinkage of repair tissue. These are observations on imaging sequences, not a catalogue of symptoms patients necessarily experience. The clinical significance of any individual finding depends on context, timing, and the degree of change — not on the finding's presence alone.

Set against those observations, MOCART scores in the broader evidence base range from 70 to 87. MOCART is a standardised scale used to assess how well repair tissue fills the defect, running from 0 to 100; scores in that band indicate good-to-excellent fill in most cases.

Patients should expect MRI review as part of monitoring regenerative scaffold treatment. Some imaging features — early bone marrow signal change, for instance — are recognised stages of biological remodelling rather than signs that treatment has failed. A consultant-led review of the scan is the appropriate setting in which to interpret what any finding means for an individual patient.

How to assess whether ChondroFiller is right for your joint

Deciding whether ChondroFiller® is appropriate starts with understanding two practical realities about how it is accessed in the UK.

First, the regulatory context. ChondroFiller® holds CE Class III designation under EU Medical Device Regulation — the highest-risk category, carrying the most demanding pre-market and post-market evidence requirements before a device reaches patients. It is not FDA-approved and is not available through the NHS; in the UK it is imported under individual private prescription, and is not covered by major private medical insurers including Bupa and AXA. Patients access it privately.

Second, the safety data reviewed in previous sections applies specifically to carefully selected patients. That selection is not a formality — it is the mechanism by which the safety record is achieved. Defect size, joint condition, surrounding cartilage health, and individual medical history all determine whether the evidence applies to a given patient.

Consultants at MSK Doctors' clinics in Sleaford and Grantham — and through the London Cartilage Clinic for patients based in London — can carry out that assessment without a GP referral. If you would like to find out whether you meet the criteria, appointments can be booked directly at mskdoctors.com.